|Clinuvel Pharmaceuticals Ltd., of Melbourne, Australia||Scenesse (afamelanotide)||Melanocyte stimulating hormone ligand||Erythropoietic protoporphyria||Drug added to the national health basket of products reimbursable in Israel|
|Genmab A/S, of Copenhagen, and Seagen Inc., of Bothell, Wash.||Tisotumab vedotin||Antibody-drug conjugate targeting tissue factor||Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy||Submitted BLA to the FDA|
|Moderna Inc., of Cambridge, Mass.||COVID-19 Vaccine Moderna||mRNA-based vaccine||COVID-19 prophylaxis||Qatar Ministry of Public Health issued an emergency use authorization|
|Oryzon Genomics SA, of Madrid||Iadademstat||LSD1 inhibitor||Acute myeloid leukemia||FDA granted orphan drug designation|
|Polaryx Therapeutics Inc., of Paramus, N.J.||PLX-300||Deaminated product of phenylalanine||Krabbe disease||FDA granted rare pediatric and orphan drug designations|
For more information about individual companies and/or products, see Cortellis.